We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Rare Genetic Variants Can Contribute to Ischemic Heart Failure

By LabMedica International staff writers
Posted on 29 Dec 2020
Print article
Image: Illustration of Normal Heart versus Heart with Dilated Cardiomyopathy (Photo courtesy of Medical gallery of Blausen Medical).
Image: Illustration of Normal Heart versus Heart with Dilated Cardiomyopathy (Photo courtesy of Medical gallery of Blausen Medical).
Heart failure affects about 40 million people globally, and most cases are due to ischemic heart disease, hypertension, or cardiomyopathies. Cardiomyopathies have been traced to rare variants in genes that encode sarcomere or cytoskeletal proteins, channels, or desmosomes, while genome-wide association studies have underscored common variants linked to heart failure.

Mendelian genetic conditions may represent an important subset of complex late-onset diseases such as heart failure, irrespective of the clinical presentation. Sequencing studies have identified causal genetic variants for distinct subtypes of heart failure (HF) such as hypertrophic or dilated cardiomyopathy. However, the role of rare, high-impact variants in HF, for which ischemic heart disease is the leading cause, has not been systematically investigated.

Medical scientists at the Columbia University Medical Center (New York, NY, USA) and their international colleagues sequenced the exomes of 5,942 people with heart failure from the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) and the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) clinical trials. The mean age (± SD) was 68.9 ± 9.9 years and 4,213 (70.9%) were male. Most of the patients in the CORONA and CHARM trial had heart failure with reduced ejection fraction, though a portion of the CHARM study patients had heart failure with preserved ejection fraction. The studies included 13,156 unrelated controls.

The team reported that in their analysis of all heart failure subtypes, the TTN gene reached study wide significance, with the strongest association in a dominant protein truncation variant model. Protein truncation variants in TTN are a known cause of cardiomyopathy, particularly dilated cardiomyopathy. Most of the cardiomyopathy-associated variants cluster in the distal exons, and the likelihood that a variant is pathogenic can be captured by the proportion spliced-in (PSI) metric. More than 55% of heart failure patients with TTN-truncating variants with high PSI scores had ischemic heart disease as their primary etiology, suggesting that even though TTN variants are only known to cause nonischemic cardiomyopathies, they are enriched among heart failure patients with ischemic disease, as compared to controls.

The team also noted that the TET2 gene reached significance in a protein truncation variant model among the subgroup with heart failure with reduced ejection fraction from the CORONA trial. In a diagnostic analysis of 41 known cardiomyopathy genes, they uncovered 204 diagnostic variants in 201 of 5,916 heart failure patients. Large portions (61.3%) of the diagnostic variants were TTN-truncating variants. Among people with ischemic heart disease, they uncovered diagnostic variants in a number of dilated cardiomyopathy genes like TTN, DSG2, and BAG3.

The authors concluded that an increased burden of diagnostic Mendelian cardiomyopathy variants in a broad group of patients with HF of mostly ischemic etiology compared with controls was observed. This work provides further evidence that Mendelian genetic conditions may represent an important subset of complex late-onset diseases such as HF, irrespective of the clinical presentation. The study was published on December 16, 2020 in the journal JAMA Cardiology.

Related Links:
Columbia University Medical Center

Print article


Molecular Diagnostics

view channel
Image: Blood smear from a P. falciparum culture: several red blood cells have ring stages inside them while close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)

Panel of MicroRNAs Differentiates Uncomplicated and Severe Malaria in Children

MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of severe malaria. MiRNAs comprise a class of about 20 n... Read more


view channel
Image: BioProfile FLEX2 Cell Culture Analyzer (Photo courtesy of Nova Biomedical)

Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer

Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.